Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.36 |
| ▸ | PLAU | P00749 | 3/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955548 | 0.86 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5954941 | 0.86 | ALDH1A1 (0.38) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5955601 | 0.85 | CHRNA7 (0.33) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5954901 | 0.85 | ELANE (0.37) | ELANEPLAUCHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5954835 | 0.83 | ALDH1A1 (0.30) | CHRNA7 | |
| SCHEMBL5955510 | 0.83 | ALPI (0.41) | CHRNA7CHRNB2CHRNA4HSD11B1 | |
| SCHEMBL5954797 | 0.82 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL5955037 | 0.81 | CHRNA7 (0.38) | CHRNA7CHRNB2CHRNA4HSD11B1 | |
| SCHEMBL5955655 | 0.81 | NAMPT (0.38) | CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL5955128 | 0.80 | ROCK2 (0.37) | CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | PFIZER INC | 2006-06-01 | — | — | US | claimed |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | PIOTROWSKI DAVID W (US) | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116395-A1 | 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease | CYP7B1, P2RX7, CYP3A7 | ELANE 2587/4885PLAU 2784/4885CHRNA7 8/4885 |
| US-20040087616-A1 | 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease | CYP1B1, TPMT, CYP7B1 | ELANE 1279/4885PLAU 3337/4885CHRNA7 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.